EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis

Meghana Moodabagil, Robert Easterling, Jing Peng, Hamzah Abu-Sbeih iD, Alexa Meara iD, Edwin Donnelly iD, Dwight H Owen iD, Kevin Ho iD

The Oncologist · 04.11.2024 · 29 (11) · e1575-e1585

DOI: 10.1093/oncolo/oyae147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 17.06.2024. Verfasst von Meghana Moodabagil und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, The Ohio State Wexner Medical Center, Columbus, OH 43210, United States. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Pneumonia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) have revolutionized cancer care with incredible reductions in mortality. One of the most devastating complications of treatment is ICI-related pneumonitis (ICI-p). Despite this, little is known regarding risk factors for severe pneumonitis and treatment effectiveness of various therapeutic options for steroid-refractory disease. To address this, we conducted a retrospective study on patients with cancer who developed ICI-p.

Methods

We examined consecutive patients who received ICIs and developed ICI-p. Risk factors of interest for severe disease and steroid-refractory ICI-p, including pre-treatment pulmonary function tests (PFTs) and chest imaging, were compared between patients with severe (grades 3-5) and mild (grades 1-2) pneumonitis. The clinical and treatment courses for patients with steroid-refractory ICI-p were recorded.

Results

A total of 132 patients developed ICI-p, with 60 patients having mild and 72 with severe disease. We found that lower forced vital capacity percent predicted (66.24 vs 85.05, P = .05), lower total lung capacity percent predicted (85.23 vs 99.71, P = .13), and specific radiographic patterns on pre-treatment chest imaging were predictors of severe disease. Initial corticosteroid dose of less than 1 milligram per kilogram prednisone equivalent (P = .14) was correlated with partially steroid-responsive or steroid-refractory ICI-p. Ten patients had steroid refractory ICI-p, and those who received IVIG alone as the immune suppressant beyond corticosteroids had improved survival (P = 05).

Conclusions

We are the first to identify pre-treatment PFTs and chest imaging abnormalities as risk factors for severe ICI-p. We also found that lower corticosteroid doses were associated with partially steroid-responsive and steroid-refractory ICI-p. Larger, prospective studies are needed to validate our results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsPneumoniaHumansMaleFemaleAgedRetrospective StudiesRisk FactorsMiddle AgedAged, 80 and overSteroidsAdultNeoplasms

Stichwörter der Autor:innen

checkpoint inhibitor pneumonitisimmune checkpoint inhibitorsimmune-related adverse eventssteroid refractory pneumonitis

Substanzen

Immune Checkpoint InhibitorsSteroids

Autor:innen und Institutionen

  • Department of Internal Medicine, The Ohio State Wexner Medical Center, Columbus, OH 43210, United States.
  • Department of Pulmonary, Critical Care, and Sleep Medicine, Medical University of South Carolina, Charlestown, SC 29425, United States.
  • Center for Biostatistics, The Ohio State University, James Comprehensive Cancer Center, Columbus, OH 43210, United States.
  • Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, James Comprehensive Cancer Center, Columbus, OH 43210, United States.
  • Division of Radiology, The Ohio State Wexner Medical Center, Columbus, OH 43210, United States.
  • Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State Wexner Medical Center, Columbus, OH 43210, United States.

ORCID-Profile: Hamzah Abu-Sbeih, Alexa Meara, Edwin Donnelly, Dwight H Owen, Kevin Ho

Zitieren

APA

Moodabagil, M., Easterling, R., Peng, J., Abu-Sbeih, H., Meara, A., Donnelly, E., Owen, D. H., & Ho, K. (2024). Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis. The Oncologist, 29(11), e1575-e1585. https://doi.org/10.1093/oncolo/oyae147

Vancouver

Moodabagil M, Easterling R, Peng J, Abu-Sbeih H, Meara A, Donnelly E, et al. Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis. The Oncologist. 2024;29(11):e1575-e1585. doi:10.1093/oncolo/oyae147

BibTeX
@article{Moodabagil2024,
  author = {Moodabagil, Meghana and Easterling, Robert and Peng, Jing and Abu-Sbeih, Hamzah and Meara, Alexa and Donnelly, Edwin and Owen, Dwight H and Ho, Kevin},
  title = {Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {11},
  pages = {e1575--e1585},
  doi = {10.1093/oncolo/oyae147}
}
Kostenlos starten →